Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protagenic TherapeuticsPTIX +8.02%22 Buyback Yield % is -127.69 as of Aug. 01, 2026. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Protagenic Therapeutics ranks worse than 91.7% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTIX vs CERO, CYTOF, CARM: Buyback Yield % Comparison
For the Biotechnology subindustry, Protagenic Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagenic Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Protagenic Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagenic Therapeutics (PTIX) has a Buyback Yield % of -127.69 as of Aug. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Protagenic Therapeutics and its competitors. According to the industry distribution chart, Protagenic Therapeutics ranks #674 out of 735 companies in the Biotechnology industry, placing it in the top 91.7%.
Is Protagenic Therapeutics' Buyback Yield % too high?
Protagenic Therapeutics' current Buyback Yield % is -127.69. Based on the distribution chart, Protagenic Therapeutics ranks #674 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Buyback Yield % compare to CERO and CYTOF?
According to the Biotechnology industry distribution chart, Protagenic Therapeutics ranks #674 out of 735 companies for Buyback Yield %. This places Protagenic Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current Buyback Yield % is -127.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Buyback Yield % of -127.69. The current Buyback Yield % is -127.69. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Buyback Yield % is -127.69 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score
Get the complete analysis for PTIX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTIX has been successfully added to your 
